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Background aims. Dendritic cells (DCs) are the most potent antigen presenting cells of the immune system and have been
under intense study with regard to their use in immunotherapy against cancer and infectious disease agents. In the present
study, DCs were employed to assess their value in protection against live virus challenge in an experimental model using
lethal and latent herpes simplex virus (HSV) infection in Balb/c mice. Methods. DCs obtained ex vivo in the presence of
granulocyte-macrophage colony-stimulating factor and interleukin-4 were loaded with HSV-1 proteins (DC/HSV-1
vaccine). Groups of mice were vaccinated twice, 7 days apart, via subcutaneous, intraperitoneal or intramuscular routes with
DC/HSV-1 and with mock (DC without virus protein) and positive (alum adjuvanted HSV-1 proteins [HSV-1/ALH])
control vaccines. After measuring anti-HSV-1 antibody levels in blood samples, mice were given live HSV-1 intraperitoneally
or via ear pinna to assess the protection level of the vaccines with respect to lethal or latent infection challenge. Results.
Intramuscular, but not subcutaneous or intraperitoneal, administration of DC/HSV-1 vaccine provided complete protection
against lethal challenge and establishment of latent infection as assessed by death and virus recovery from the trigeminal
ganglia. It was also shown that the immunity was not associated with antibody production because DC/HSV-1 vaccine, as
opposed to HSV-1/ALH vaccine, produced very little, if any, HSV-1-specific antibody. Conclusions. Overall, our results may
have some impact on the design of vaccines against genital HSV as well as chronic viral infections such as hepatitis B virus,
hepatitis C virus and human immunodeficiency virus.
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Dendritic cells (DCs) are known as the most potent
cells with respect to capturing and processing of
antigens and have been the subject of intense interest
in generating unique immune responses against
tumor antigens, a treatment modality known as
cancer or tumor vaccines (1). This treatment
modality for cancer patients is based on a vaccine
formulation generated ex vivo by first differentiating
autologous monocytes into immature DCs (iDCs) in
the presence of cytokines (granulocyte-macrophage
colony-stimulating factor [GM-CSF] and interleukin
[IL]-4) and then loading them with tumor tissue
lysates or tumor-specific antigens to prepare so-called
tumor antigen-loaded mature DCs (mDCs) for clin-
ical use. The use of vast numbers of such formula-
tions has suggested that tumor antigen-loaded DCs
may provide tumor eradication in experimental and
clinical settings (1e3). However, numerous issues
with regard to the methods of preparation and use of
DC vaccines have not yet been optimized. TheseCorrespondence: Dr. Mehdi Ghasemi, Department of Molecular Biology and G
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DCs, the selection of the target antigens and their
loading technique, and the route and number of
injections (4,5).
Despite several uncertainties with regard to
preparing DC vaccines, a similar strategy in parallel
with anti-cancer studies has been contemplated for
diseases caused by microorganisms (6,7). The first
sample of a DC vaccine against infectious agents was
for the treatment of Borrelia burgdorferi spirochete
infection in experimental animals (8). DC vaccines
subsequently were studied in various other experi-
mental viral and non-viral infectionmodels, including
lymphocytic choriomeningitis virus, herpes simplex
virus (HSV) type 2 and influenza virus (9e11) as well
as bacterial, fungal and parasitic pathogens (12e15).
Despite the vast heterogeneity of the microorganisms
used, antigen-loaded DCs were highly competent in
inducing both humoral and T cell-mediated re-
sponses. Consequently, DC-based vaccination has
emerged as a promising tool to augment immuneenetics, Bilkent University, Ankara, Turkey. E-mail: ghassemi@gmail.com
ublished by Elsevier Inc. All rights reserved.
DC vaccine for herpes simplex virus 353responses in persistent infections caused by viruses
such as hepatitis B virus (HBV), hepatitis C virus
(HCV) and human immunodeficiency virus (HIV)
in experimental and clinical settings (16,17). DC-
based vaccination was reported to be safe and
feasible and showed evidence of immunogenicity in
HIV-1-positive individuals (16,18e20). In the case
of HCV infection, in which it is thought that the virus
impairs DC maturation and functions, it was
proposed that DCs loaded and matured ex vivo with
HCV proteins could prime naïve T cells or stimulate
existing HCV-specific cellular immunity or both
(21,22). In a more recent study, DCs loaded with
recombinant HCV core proteins and peptides
provided strong humoral and cellular response (23).
Another study showed that DCs transfected with
adenovirus having HCV NS3 protein genes elicited
CD4þ TH1 and CD8
þ T-cell responses in different
mouse species (24). A situation similar to HCV holds
true for HBV, for which insufficient specific cell
response is thought to be responsible for persistence
of the virus (25,26). It was reported that autologous
DCs loaded with hepatitis B virus surface antigen
(HBsAg) were safe and able to induce anti-HBs
response in phase I clinical studies performed on
healthy volunteers (27). Another study showed that
patients with chronic HBV infection who had
received HBsAg-loaded DCs had repressed HBV
replication and decreased viral load in serum,
developed anti-HBV antibody and lost HBeAg (28).
Further studies demonstrated that insufficient DC
activity in hepatitis patients could be restored by DC
vaccine loaded with HBcAg and HBsAg and that
autologous T-lymphocyte proliferation and antigen-
specific interferon (IFN)-g production could be
increased (29). Vaccination of patients with HBV-
related hepatocellular carcinoma with HBcAg- and
HBsAg-loaded DCs induced co-stimulatory mole-
cule synthesis (CD40, CD80 and CD86) and stim-
ulated autologous T-cell proliferation and IFN-g
secretion, suggesting that a DC vaccine could be
promising for the treatment of HBV-based liver
cancers (30).
Animal models for the development and evalua-
tion of DC-based vaccines against chronic and latent
viral infections are limited. The most appropriate
animal models to study the features of a latent viral
infection are HSV guinea pig/mouse models
described previously (29,31). The problems of DC
vaccine preparations discussed in the field of cancer
immunotherapy are also valid for infectious diseases.
Using the well-established HSV-mouse model
(29,31), we set out to optimize some parameters
including the route of injection to obtain a better
immune response against active and latent viral
infections by employing DC vaccines.Methods
Cell and virus strains
TheWall and F strains of HSV-1 were propagated and
titrated in Vero cells (Vircell, Granada, Spain) as
described previously (32) using minimal essential
medium (MEM) supplied with 2% fetal bovine serum
(FBS). Briefly, the infected cells were collected and
subjected to freeze and thaw cycles twice. After
centrifugation, the cell-free supernatant was harvested
and stored at80C as a stock virus pool. The titer was
determined by plaque assay using Vero cells grown to
confluence in 24-well plates. The wells were infected
with viral serial dilutions (101e108) in duplicates.
After incubation at 37C in 5% carbon dioxide (CO2)
for 1 h, the inoculumwas removed, and plaque overlay
medium (double-strength MEM and 1.6% carboxy-
methylcellulose mixed 1:1) was added to each well.
After incubation for 72 h, plates were rinsed and
stained, and the plaques were counted. Plaque titers
(plaque-forming units/mL) were calculated directly
from the dilution factor. Median lethal dose of the
stock virus was determined in Balb/c mice 6e8 weeks
old infected with 10-fold virus dilutions (102e107)
by the intraperitoneal route as described (32).HSV-1 protein preparation
HSV-1 proteinswere prepared by propagation ofHSV-
1 F strain in Vero cells and subsequent zwitterionic
detergent extraction by using Empigen (Albright &
Wilson,Hull,UK) asdescribed elsewhere (32). Briefly,
HSV-1-infected Vero cells showing 80e90% cyto-
pathic effect were harvested and pelleted by centri-
fugation. The pellets were rinsed twice with cold
phosphate-buffered saline (PBS) and re-suspended
in 2.5% Empigen in PBS. Following sonication,
insoluble material was removed by high-speed
centrifugation (32,000 rpm for 1 h), and the resulting
detergent-protein extract was dialyzed against PBS.
A mock infected Vero cell protein extract (crude
extract) was also prepared in parallel for use as a virus
negative control antigen source. For partial purifica-
tion, both types of extracts were subjected to centrifu-
gation (26,000 rpm for 5 h) on a 20% sucrose cushion.
Thepartially purified virusproteinmixture contains the
four major HSV-1 glycoproteins, gB, gC, gD and gE,
and several other viral andnon-viral proteins (32).After
determination of the total protein content by the
modified Lowrymethod, theHSV-1 andmock antigen
preparations were stored at80C until use.Generation of DCs
Bone marrow-derived DCs were obtained from
Balb/c mice as described earlier (33) with some
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weeks old were flushed with RPMI medium, and red
blood cells were subsequently lysed using ammonium
chloride. Cells (1  106 cells/mL) were cultured in
24-well plates in complete RPMI medium supple-
mented with 20 ng/mL each of recombinant mouse
GM-CSF and IL-4 (PeproTech, London, UK), 5%
FBS, 50 mM 2-mercaptoethanol and penicillin/strep-
tomycin (100 mg/U/mL). After 6 days of culture at
37C in 5% CO2, with two changes of the medium on
day 2 and day 4, semi-adherent and non-adherent cells
were harvested by pipetting and used as iDCs for
pulsing with the HSV-1 proteins as described subse-
quently. For the maturation of DCs (mDCs) before
use in vaccination studies, antigen-loaded iDCs were
cultured further for 24 h at 37C in 5% CO2 in RPMI
medium supplemented with recombinant mouse
TNF-a (20 ng/mL).Flow cytometry analysis of DCs
Immunophenotyping of iDCs and mDCs was per-
formed by flow cytometry (Coulter Epics XL-MCL;
Beckman Coulter, Miami, FL, USA). For each
sample, 5  105 cells were stained with specific anti-
bodies for 30 min at 4C in 20 mL of PBS containing
2% bovine serum albumin and 0.1% sodium azide,
after pre-incubation of cells with Mouse BD Fc Block
(2.4G2 clone; BD Biosciences, Istanbul, Turkey).
The following fluorescein isothiocyanate (FITC)- or
phycoerythrin (PE)-labeled monoclonal antibodies
were used: hamster anti-mouse CD11c (HL3 clone),
rat anti-mouse CD45R/B220 (RA3-6B2 clone), rat
anti-mouse CD4 (GK1.5 clone), rat anti-mouse
CD8a (53-6.7 clone), mouse anti-mouse I-A[d]
(AMS-32.1 clone), rat anti-mouse CD40 (3/23
clone), hamster anti-mouse CD80 (16-10A1 clone)
and rat anti-mouse CD86 (GL1 clone). As negative
controls, FITC- or PE-labeled species- and isotype-
matched antibodies were used: hamster Ig1-ƛ1
(G235-2356 clone), IgG2a-k/ƛ1 (R35-95 clone),
IgG2b-k/ƛ1 (A95-1 clone), IgG2b-k/ƛ1 (MPC-11
clone) and IgG2-k ƛ1 (B81-3 clone). All antibodies
were purchased from BD Biosciences Pharmingen
(San Diego, CA, USA). Data were analyzed using
Expo32 analysis software (Beckman Coulter).Loading of DCs with HSV-1 proteins and
vaccination of mice
To prepare HSV-1 antigen-loaded DC vaccine (DC/
HSV-1), 1 106 iDCs obtained after 6 days of culture
as described earlier were incubatedwith 50 mg ofHSV-
1 antigen mixture or control preparation at 37C in
5% CO2 for 3 h. The cells were rinsed with RPMI
medium three times, re-suspended in RPMI mediumsupplemented with 20 ng/mL of recombinant mouse
TNF-a, and incubated overnight as before to obtain
mDCs.Onday7, the cellswere rinsed as just described
and adjusted to 1  106/mL. Via intraperitoneal,
subcutaneous or intramuscular routes, 0.1 mL of this
suspension was administered into groups of Balb/c
mice in two dosages, 7 days apart. Two control groups
were vaccinated subcutaneouslywith (i)mock antigen-
loaded DCs prepared in a similar way to DC/HSV-1
and (ii) alum-adjuvanted HSV-1 vaccine (HSV-1/
ALH), which was prepared on the day before admin-
istration bymixing a predetermined quantity ofHSV-1
antigen mixture with an equal volume of ALH
(Superfos, Randers, Denmark). HSV-1/ALH given
subcutaneously at 20 mg/0.1 mL per mouse served as
a positive control because it is known to elicit virus-
specific antibody response and protection against
challenge with live HSV-1 (29).Measurement of antibody responses
Anti-HSV-1 antibody levels in mice vaccinated with
DC/HSV-1 or with control vaccines were assessed by
enzyme-linked immunosorbent assay (ELISA) using
serum samples obtained intra-cardially 7 days after
the second injection as described (31). ELISA plates
(Costar, High Wycombe/Buckinghamshire, UK)
were coated with 100 mL (2.5 mg total protein) of
HSV-1 antigen solution and incubated overnight at
4C. After a wash with PBS/Tween (Sigma-Aldrich,
Ankara, Turkey), 100 mL of test serum diluted 1:100 in
PBS/Tween/bovine serum albumin was added and
allowed to bind for 1 h at 37C. Plates were washed
again, and horseradish peroxidase-conjugated anti-
mouse IgG (Dako, Izmir, Turkey) was added to each
well at a dilution of 1:1000. Plates were incubated and
washed as before. Finally, 100 ml of p-phenylenedi-
amine dihydrochloride substrate in citrate phosphate
buffer was added to the wells for 15 min to allow color
development. The reaction was stopped by the addi-
tion of 2 mol/L sulfuric acid, and absorbance values
were read at 492 nm. Sera from non-vaccinated
healthy mice were used as negative controls, and sera
obtained from mice successively injected with sub-
lethal dosages of live HSV-1 were used as positive
controls. ELISA titer was calculated by (test optical
density [OD]  negative serum OD)/(positive serum
OD  negative serum OD)  dilution of serum, and
the results were given as log2 ELISA unit.Acute and latent HSV-1 infection of mice
vaccinated with DC vaccine
To assess the protective power of DC/HSV-1 vaccine
against acute or latent infection, the mice vaccinated
7 days apart with two doses of DC/HSV-1 or control
DC vaccine for herpes simplex virus 355vaccines were challenged in two different ways:
(i) For the acute infection model, different groups of
mice vaccinated via the subcutaneous, intraperito-
neal, or intramuscular route were challenged with
intraperitoneal injection of 5  median lethal dose of
live HSV-1 (Wall strain) known to cause severe acute
infection resulting in 100% death of mice within
2 weeks (31). (ii) For the latent infection model, mice
vaccinated via the intramuscular route were chal-
lenged via the ear scarification method as described
elsewhere (34,35). Briefly, 10 mL of live HSV-1 (Wall
strain at 1  105 plaque-forming units) was placed on
shaved ear pinna, the drop was spread out slightly on
the skin with the shaft of a 24-gauge needle and 10
parallel scarifications were made with the sharp edge
of the bevel through the inoculum fluid. In the latent
model of infection, infected mice were nourished
under normal conditions for 1 month and were culled
to determine the presence of latent virus or virus titers
or both in trigeminal ganglia as described next.Assays of latent infection in mice
For assay of latent infection, trigeminal ganglia of
latently infected mice were aseptically removed and
transferred into 4 mL of MEM, which was supple-
mented with 5% FBS and penicillin/streptomycin/
fungizone, and were incubated at 37C in 5%CO2 for
5 days. The ganglia were individually homogenized in
their culture medium and centrifuged at 2000 rpm for
5 min to remove debris. Resulting supernatants were
divided and either used to infect Vero cells prepared in
24-well plates as described earlier or assayed by
quantitative polymerase chain reaction (PCR) for viral
DNA. In the cell culture test, the wells were inspected
daily for the evidence of virus-induced cytopathic
effect for 10 days. The presence of cytopathic effect
indicated that the ganglion was harboring the virus
and was latently infected (36). For the quantitative
PCR test, DNAwas isolated from homogenates using
the EZ1 Virus Mini Kit v2.0 (Qiagen, Hilden,
Germany). Amplification, detection and quantitation
of HSVDNAwas carried out using the artus HSV-1/2
RG PCR Kit v1 in a Rotor-Gene Q per the manu-
facturer’s instructions, and data analysis was done by
Rotor-Gene Q software, version 1.7 (all Qiagen).
HSV-1 viral loads for the test samples were presented
by averaging the logarithms of the titers (copies/mL).Results
Generation and functional assessment of murine
bone marrow-derived DCs
Morphologically, bone marrow-derived DCs had
typical shapes of mDCs such as cytoplasmic dendriticprojections (Figure 1A), and immunophenotypically
they expressed several DC-associated cell surface
markers as determined by fluorescence-activated cell
sorter analysis (Figure 1B,C). DC populations used in
immunizations lacked CD45R, CD4 and CD8 but
expressed high levels of CD11c (82.7%), MHC II
(58.1%), CD80 (89.3%) and CD86 (28.3%), typical
features of mDC markers.
To assess the functionality of DCs, we used
FITC-labeled antigen uptake assay as described
earlier and found that iDCs, as opposed to mDCs,
take up FITC-labeled dextran highly efficiently
(Figure 2). iDCs generated on day 6 in the presence of
GM-CSF and IL-4 were highly capable of antigen
uptake (80.9%), whereas DCs produced on matura-
tion of iDCs with TNF-a were not as efficient
(29.8%). The endocytic capacity of iDCs was inves-
tigated further by fluorescence microscopy using
FITC-labeled Staphylococcus aureus particles, and the
results showed that iDCs generated under the
conditions described were highly competent in
capturing foreign particles (data not shown).DC/HSV-1 vaccine induces protection against
acute HSV-1 infection
DCs generated in our study with features with regard
to morphology, antigen uptake efficiency and rele-
vant surface antigen expressions such as CD11c,
MHC II and co-stimulatory markers of CD80 and
CD86 were loaded with partially purified HSV-1
antigens as described earlier to obtain DC/HSV-1
vaccine. The vaccine containing 5  105 mDCs
per dosage was administered twice, 7 days apart, to
Balb/c mice via subcutaneous, intraperitoneal and
intramuscular routes. Control groups received either
DCs given subcutaneously at similar numbers but
loaded with Vero cell extract (negative control) HSV-
1/ALH prepared as described earlier.
Serum samples were analyzed 2 weeks after the last
vaccination for HSV-1-specific antibodies using
a sensitive ELISA procedure. As shown in Figure 3,
subcutaneous vaccination with mock DC preparation
induced undetectable anti-HSV-1 antibody response,
whereas HSV-1/ALH vaccination elicited, as ex-
pected, high titers of HSV-1-specific IgG response.
However, regardless of the route it was given, the DC/
HSV-1 vaccine induced an anti-HSV-1 antibody
response that was comparable to themockDC vaccine
(P > 0.5) but markedly less than the HSV-1/ALH
vaccination (P< 0.05), indicating thatB-cell responses
were not stimulated as efficiently as when HSV-1
antigens were given together with alum adjuvant.
We wanted to find out if DC/HSV-1 vaccine
could induce protective immunity to an acute lethal
infection challenge despite the fact that it did not
Figure 1. Microscopy and immunophenotype of bone marrow-derived mononuclear cells cultured in the presence of GM-CSF and IL-4 for
6 days followed by 1 more day of culturing for maturation with TNF-a. (A) DCs show distinct membrane outgrowths (white arrows).
(B) Representative fluorescence-activated cell sorter histogram of the gated large and granular cell population. (C) Expression percentages of
CD4, CD8, CD11c, MHC II, CD80 and CD86 surface markers.
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vaccinated with two dosages 1 week apart of the DC/
HSV-1 vaccine and control vaccines (mock DC and
HSV-1/ALH) were challenged 7 days later with
a lethal dose of HSV-1. In this acute infection model,
naïve mice die of severe HSV-1 infection over 10e15
days. In our challenge study, mice in the control
group vaccinated with mock DCs were lost on chal-
lenge with live HSV-1, whereas 60% of mice in the
group receiving HSV-1/ALH vaccine survived
(Figure 4). However, the degree of protection affor-
ded by DC/HSV-1 varied; subcutaneous and intra-
peritoneal administration of the vaccine endowed as
much protection as the HSV-1/ALH vaccine, whereas
vaccination via the intramuscular route resulted in
100% survival. We corroborated our findings witha repeat experiment, which suggested that the
protection levels provided by the DC/HSV-1 vaccines
given subcutaneously or intraperitoneally were not
statistically significant compared with the survival rate
obtained with HSV-1/ALH vaccination (P > 0.05).
Although the difference between the administration
routes of the DC/HSV-1 vaccine was evident only for
intramuscular injection in regard to survival rates, the
DC/HSV-1 vaccine, which afforded complete
protection against lethal challenge with live virus, was
not effective enough to induce anti-HSV-1 IgG
response in mice. In other words, mice responding to
HSV-1/ALH vaccination with high levels of anti-
HSV-1 antibody were not protected, albeit statisti-
cally not significant, as efficiently as themice receiving
the DC/HSV-1 vaccine intramuscularly, indicating
Figure 2. Flow cytometry analysis of the antigen uptake capacity of DCs at various time points of culture. Cells on the 3rd day culture show
insignificant antigen uptake, whereas DCs generated on the 6th day are in an immature state (iDC) and are highly efficient in antigen uptake
compared with TNF-a matured DCs (mDC), which are expected to show less ability with respect to antigen capturing activity.
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protection.DC/HSV-1 vaccine induces protection against
establishment of latent HSV-1 infection
The hallmark of HSV is that after infection of
epithelial cells on the skin and mucosal surface, the
virus enters the sensory nerve endings and travels via
retrograde transport along nerve axons to the dorsal
root ganglia where latency is established. One of the
main goals of a HSV vaccine has been to prevent the




























Figure 3. Levels of anti-HSV-1 antibody responses in groups of
mice immunized via the subcutaneous (s.c) route with HSV-1/
ALH and with DC/control vaccine or with HSV-1 DC/HSV-1
vaccine given via subcutaneous (s.c), intraperitoneal (i.p) and
intramuscular (i.m) routes. ELISA antibody levels are expressed as
log2 values ( SEM).In our study, because the DC/HSV-1 vaccine
conferred complete protection in the lethal infection
model, we wanted to test if DC/HSV-1 vaccine could
also protect mice from the establishment of latent
infection. To this end, in a single study, mice were
first given two doses, as described earlier, of DC/
HSV-1, mock DCs and HSV-1/ALH intramuscu-
larly and challenged with live HSV-1 after 7 days
percutaneously via one ear as described earlier to
allow establishment of the latent infection in
trigeminal ganglia. After 1 month of nourishing of


















Figure 4. Protection of mice from acute or lethal HSV-1 infection
by vaccination via the subcutaneous (s.c) (n ¼ 10) route with
HSV-1/ALH and with DC/control vaccine (n ¼ 8) or with HSV-1
DC/HSV-1 vaccine given via subcutaneous (s.c) (n ¼ 10), intra-
peritoneal (i.p) (n ¼ 8) and intramuscular (i.m) (n ¼ 10) routes.
Survival rates were estimated according to the Kaplan-Meier
method and were compared using the log-rank test (Cox-Mantel
using GraphPad Prism [GraphPad Software, San Diego, CA,
USA]). *P < 0.05; **P < 0.01; ***P < 0.001.
Table I. Incidence of latent infection in trigeminal ganglia
following inoculationa by scarification of the ear pinna in mice




Assay of latent infection in ganglia




By quantitative PCR testb




DC/control 5/8 5.8  0.3 (5/8)
DC/HSV-1 0/7d <0.9  0.2 (0/7)
HSV-1/ALH 2/6e 4.6  0.4 (2/6)
P values calculated by Fisher exact test.
aChallenged via ear pinna with 105 plaque-forming units HSV-1
(strain Wall) 7 days after second immunization.
bTrigeminal ganglia cultivated for 5 days were homogenized and
seeded onto host cells, or used in quantitative PCR test as
described in the methods section.
cCalculated by averaging the logarithms of the titers (copies/mL).
dP < 0.05 compared with DC/control group.
eP > 0.05 compared with DC/HSV-1 and DC/control group.
358 M. Ghasemi et al.as described in the methods section. As summarized
in Table I, the results of both the cell culture testing
of live virus in ganglion homogenates and the real-
time PCR quantification test showed that vaccination
of mice with DC/HSV-1 could also induce 100%
protection as reflected by the absence of virus in
trigeminal ganglia indicating that the vaccine was
able to arrest the virus at the entry site or prevent
traveling to the trigeminal ganglia.
Compared with the DC/HSV-1 vaccine, the
HSV-1/ALH vaccine and the mock DC preparation
were markedly less efficient in preventing the estab-
lishment of latency. Of eight mice, two vaccinated
with the HSV-1/ALH vaccine and five vaccinated
with the mock DC preparation were latently infected
(Table I). Although the level of protection from the
establishment of viral latency by DC/HSV-1 vacci-
nation was significantly higher (P ¼ 0.0256) than the
rate of latency seen in the mock DC vaccination
group (five mice positive for virus out of eight), this
high level of protection achieved with the DC/HSV-1
vaccine should be interpreted with some caution.
Not only was there no statistically significant differ-
ence between the DC/HSV-1 and HSV-1/ALH
vaccines (P > 0.05), but also no repeat experiment
was performed to confirm the findings.Discussion
The salient feature of the present study is that DCs
loaded with protein antigens induce a variable
immune response in regard to generation of antigen-
specific antibody and protection in a host, at least in
the model employed here. This conclusion was basedmainly on the findings that HSV-1-loaded DCs
conferred protection against live virus challenge
despite the fact that they were not as efficient as HSV-
1/ALH in eliciting virus-specific antibody response. It
was shown that immune response in regard to
protection was more pronounced if antigen-loaded
DCs were administered intramuscularly as opposed
to subcutaneously or intraperitoneally. Our results
may have some implications in design and use of
antigen-loaded DC vaccines not only for infectious
diseases but also for anti-cancer studies. DCs are
intensely tested in cancer studies, and the issues
relating to design and use of DC vaccines have been
the subject of discussions in several reports (37e39).
In several experimental and clinical studies, antigen-
loaded DCs were usually administered via subcuta-
neous, intravenous, intranodal or intradermal routes
(38). Although the administration routes were not
compared, it has been shown in some reports that
DCs loaded with HCV core protein administered by
the intramuscular and intraperitoneal routes induced
a strong cytotoxic T-cell response (40,41). It appears
that inherent problems (i.e., administration route,
number of injections, type of antigen, number of cells)
in using DC vaccines are also valid in the case of DC
vaccines targeted for infectious agents.
In regard to HSV, it is known that administration
of viral proteins, at least together with different adju-
vants in various amounts and via different routes, has
a major impact on generating a protective immune
response (31). However, the issue of which type of
immune response induces better protection against
challenge is controversial. The relationship between
higher antibody levels and protection obtained by
active or passive immunization has been supported in
more recent studies (11,42e45) as well as previous
studies (29,46e48). Several reports suggest that
HSV-specific antibodies do not always confer
protection (49e53); this is also true for latently
infected individuals in whom the presence of circu-
lating high levels of specific antibodies, even if they are
of the neutralizing type, does not correlate with
protection suggesting that antibody to the virus may
be useless (54).
As shown in our study, although the HSV-1/ALH
vaccine induced significantly high levels of anti-
HSV-1 antibody response, it was markedly less effi-
cient than the DC/HSV-1 vaccine, which induced an
antibody response comparable to the mock DC
vaccine but was highly potent in protection against
virus challenge. Other studies also demonstrated that
DC vaccines prepared by virus or virus proteins do
not induce high levels of antibody response (10,41).
However, a single study reported that DCs loaded
with gB/gD proteins of HSV-2 induced high levels
of specific antibody response, but the observed
DC vaccine for herpes simplex virus 359protection was attributed to the role of CD4þ
cells and IFN-g cytokine response (11). For HSV
infection, it has been argued that CD4þ and CD8þ
T-cell responses are more essential than antibody
response (including the neutralization type) for the
prevention of primary and latent infections (55,56).
In a more recent study, it was shown that CD4þ T
cell-mediated viral clearance was relatively more
important in preventing primary and latent infections
(57). After activation by local tissue-resident DCs,
TH1 cells were reported to mediate antiviral protec-
tion through local secretion of IFN-g rather than
FasL or perforin related direct lysis (58). One of our
findings suggests that despite eliciting an insignifi-
cant anti-HSV-1 antibody response, the high level of
protection conferred by the DC/HSV-1 vaccine
could be attributed to induction of a CD4þ T cell-
mediated immune response. As mentioned before,
vaccination of mice with HSV-2 gB/gD-loaded DCs
was reported to protect mice against intravaginal live
HSV-2 challenge through CD4þ T-cell response that
relied on IFN-g secretion (11).
One of the main goals of developing HSV vaccines
has been to produce an optimal immunity that can
prevent establishment of latent infection or decrease
HSV reactivation from latency or decrease virus
replication after a reactivation event. Various experi-
mental models have shown that prevention of latent
infection to some extent is possible (31,34,35,59). In
our study, using a completely different antigen
presentation model, we observed that the level of
protection from the establishment of viral latency by
the DC/HSV-1 vaccine was significantly different
than the rate of latency (five mice positive for virus out
of eight) seen in the mock DC vaccine group.
However, this high level of protection achieved with
the DC/HSV-1 vaccine should be interpreted with
some caution. There was no statistically significant
difference between the DC/HSV-1 and HSV-1/ALH
vaccines. Our results require further confirmation by
repeat experiments using large numbers of animals.
In conclusion, efforts to design an effective vaccine
against HSV-1 and HSV-2 have created a plethora of
formulations among which attenuated live virus
models, replication-defective HSV-1 vaccines, adju-
vanted glycoprotein vaccine preparations and DNA
vaccines have been assessed in experimental and clin-
ical studies (60,61). Despite the promising results of
several candidate vaccines in animal studies, most
clinical trials have been disappointing (62,63), and
further strategies are warranted in the pursuit of
a potent HSV vaccine. The use of DCs in designing
vaccines for both cancer and infectious diseases may
provide better alternatives in this regard. Taken
together, our findings obtained using DCs loaded with
partially purified HSV-1 proteins may be relevant infuture HSV vaccine formulations and in designing
vaccines for infectious agents including HIV, HBV
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